Please login to the form below

Not currently logged in
Email:
Password:

Azafaros expands executive team with three senior hires

Kyle Landskroner, Ruben Giorgino and Louise Kooij join the team

Biotech company Azafaros has expanded its executive management team with a trio of senior hires.

Kyle Landskroner (pictured above) has been appointed head or preclinical drug development, joining the team from Novartis. At Novartis, he held the position of director, global integration & separation office.

Prior to this, he served as director portfolio management, global drug development, portfolio strategy and innovation at Novartis.

In this role, he led value-driven decisions analyses for the development portfolio, various clinical projects within therapeutic area franchises and strategic reviews.

Also joining the senior team is Ruben Giorgino (pictured above), who has been appointed head of clinical research and development.

He joins from Helsinn Group, where he held the position of global head of clinical research and development. Prior to this, he held global clinical development and medical affairs leadership roles at Actelion Pharmaceuticals.

Rounding out the new hires is Louise Kooij, who joins as head of finance and operations from Sanofi-Genzyme.

While at Sanofi, she served as head of rare diseases, Central and Eastern Europe – in this role, she led all commercial activities for rare disease-related programmes in those regions.

Before this, she held the position of head of business operations Europe at Sanofi-Genzyme Europe, after working as vice president, business control and analysis at Sanofi-Genzyme in Boston, US.

“Attracting these experienced and skilled executives to the management team of Azafaros is a major step for the company as our lead program AZ-3102 for neurodegenerative lysosomal storage disorders is progressing towards first-in-human studies,” commented Olivier Morand, chief executive officer of Azafaros.

“The insights and experience provided by Kyle, Ruben and Louise across the spectrum from R&D through finance and business will help us to accelerate our efforts to develop novel disease-modifying treatment modalities,” he added.

Article by
Lucy Parsons

1st July 2020

From: Research

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Springer Nature

Operating in 50+ countries, we’re a leading research, educational, and professional publisher dedicated to advancing scientific discovery. Whether you’re looking...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...